BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JS111 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JS111\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07518160-2047@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:JS111: Phase 2 readout est. (NCT07518160)
DESCRIPTION:JS111\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS212 Plu
 s JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study\nEstimated primary
  completion: 23 April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/js111#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07518160
URL:https://assetmemo.bio/drug/js111#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940401-2047@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:JS111: Phase 1/2 readout est. (NCT06940401)
DESCRIPTION:JS111\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: JS111 i
 n Patients With Advanced NSCLC Harboring EGFR Mutations\nEstimated primary
  completion: 30 July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/js111#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06940401
URL:https://assetmemo.bio/drug/js111#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
